Literature DB >> 1368916

In-vitro cleavage of a fusion protein bound to cellulose using the soluble yscFs (Kex2) variant.

P G Seeboth1, R A Warren, J Heim.   

Abstract

In order to show site-specific cleavage of fusion proteins with an engineered soluble yscF variant, we have constructed a fusion gene encoding eglinC from Hirudo medicinalis and the cellulose-binding domain from the Cellulomonas fimi exoglucanase (Cex). The two fusion partners were separated by a Lys-Arg-containing recognition sequence for the yeast endoprotease yscF (Kex2). The fusion protein (eglinC-Cex) was expressed intracellularly in Saccharomyces cerevisiae. After disruption of the cells eglin-C-Cex was shown to bind to cellulose when present in total crude cell lysates. This step efficiently removed the majority of contaminating host proteins. While immobilized on cellulose, eglin-C-Cex could be cleaved into the expected fragments. Upon cleavage the eglinC part was released from the cellulose, while the purification tag, i.e. the cellulose binding domain, stayed bound to the cellulose matrix.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1368916     DOI: 10.1007/bf00240737

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  13 in total

Review 1.  Engineering proteins for purification.

Authors:  H M Sassenfeld
Journal:  Trends Biotechnol       Date:  1990-04       Impact factor: 19.536

2.  Pro-sequence of subtilisin can guide the refolding of denatured subtilisin in an intermolecular process.

Authors:  X L Zhu; Y Ohta; F Jordan; M Inouye
Journal:  Nature       Date:  1989-06-08       Impact factor: 49.962

3.  Isolation and characterisation of a low molecular weight inhibitor (of chymotrypsin and human granulocytic elastase and cathepsin G) from leeches.

Authors:  U Seemüller; M Meier; K Ohlsson; H P Müller; H Fritz
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1977-09

4.  Alpha-factor-leader-directed secretion of recombinant human-insulin-like growth factor I from Saccharomyces cerevisiae. Precursor formation and processing in the yeast secretory pathway.

Authors:  K Steube; B Chaudhuri; W Märki; J P Merryweather; J Heim
Journal:  Eur J Biochem       Date:  1991-06-15

5.  A large fragment approach to DNA synthesis: total synthesis of a gene for the protease inhibitor eglin c from the leech Hirudo medicinalis and its expression in E. coli.

Authors:  H Rink; M Liersch; P Sieber; F Meyer
Journal:  Nucleic Acids Res       Date:  1984-08-24       Impact factor: 16.971

6.  Regulated overproduction of alpha-amylase by transformation of the amylolytic yeast Schwanniomyces occidentalis.

Authors:  R J Dohmen; A W Strasser; R S Zitomer; C P Hollenberg
Journal:  Curr Genet       Date:  1989-05       Impact factor: 3.886

7.  Characterization and structure of an endoglucanase gene cenA of Cellulomonas fimi.

Authors:  W K Wong; B Gerhard; Z M Guo; D G Kilburn; A J Warren; R C Miller
Journal:  Gene       Date:  1986       Impact factor: 3.688

8.  Precise excision of the cellulose binding domains from two Cellulomonas fimi cellulases by a homologous protease and the effect on catalysis.

Authors:  N R Gilkes; R A Warren; R C Miller; D G Kilburn
Journal:  J Biol Chem       Date:  1988-07-25       Impact factor: 5.157

9.  Fusion to an endoglucanase allows alkaline phosphatase to bind to cellulose.

Authors:  J M Greenwood; N R Gilkes; D G Kilburn; R C Miller; R A Warren
Journal:  FEBS Lett       Date:  1989-02-13       Impact factor: 4.124

10.  In-vitro processing of yeast alpha-factor leader fusion proteins using a soluble yscF (Kex2) variant.

Authors:  P G Seeboth; J Heim
Journal:  Appl Microbiol Biotechnol       Date:  1991-09       Impact factor: 4.813

View more
  1 in total

1.  Production of autolysis-proof Kex2 protease from Candida albicans in Saccharomyces cerevisiae for in vitro processing of fusion proteins.

Authors:  Mi-Jin Kim; Bong Hyun Sung; Hyun-Jin Kim; Jung-Hoon Sohn; Jung-Hoon Bae
Journal:  Appl Microbiol Biotechnol       Date:  2022-10-05       Impact factor: 5.560

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.